EyePoint Pharmaceuticals, Inc., EYPT is showing recent insider trading activity. Public SEC records indicate that Asset Cormorant recently Bought $3,525,247 worth of shares on 5 days ago. With that said, our editors here at politicsandwallstreet.com, are adding EYPT to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of EYPT that bought $6.2M worth of shares in the last 3 months, the Insider Confidence level of EyePoint Pharmaceuticals, Inc. is trending Neutral.
Since these insiders have unique insights into what's happening at EyePoint Pharmaceuticals, Inc., this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for EYPT:
In addition, TradingView issued a rating for EYPT over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has short-term outlook.
Here is a bit more on EyePoint Pharmaceuticals, Inc., EYPT but please do your own research.
EYPT Summary: EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to EYPT, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of EYPT that bought $6.2M worth of shares in the last 3 months, the Insider Confidence level of EyePoint Pharmaceuticals, Inc. is trending Neutral.
Since these insiders have unique insights into what's happening at EyePoint Pharmaceuticals, Inc., this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for EYPT:
- Asset Cormorant - 10 percent owner, Bought $3,525,247 worth of shares on 5 days ago
- Asset Cormorant - 10 percent owner, Bought $6,964,199 worth of shares on 5 days ago
- David Jones - officer: SVP & Chief Commercial Officer, Sold $5,954 worth of shares on 2 months ago
- David Jones - officer: SVP & Chief Commercial Officer, Sold $417,653 worth of shares on 2 months ago
In addition, TradingView issued a rating for EYPT over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has short-term outlook.
Here is a bit more on EyePoint Pharmaceuticals, Inc., EYPT but please do your own research.
EYPT Summary: EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA.
- Recent Last Price: $17.57
- Price Change: $0.62, 3.66%
- Yearly Gain: 126.42%
- Market Cap: $875.53M
- P/E Ratio: -9.65
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to EYPT, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
